Graeff H - Search Results

1

Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer.

Jänicke F, Schmitt M, Graeff H. Jänicke F, et al. Among authors: graeff h. Semin Thromb Hemost. 1991 Jul;17(3):303-12. doi: 10.1055/s-2007-1002624. Semin Thromb Hemost. 1991. PMID: 1796300 No abstract available.

2

Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer.

Schmitt M, Goretzki L, Jänicke F, Calvete J, Eulitz M, Kobayashi H, Chucholowski N, Graeff H. Schmitt M, et al. Among authors: graeff h. Biomed Biochim Acta. 1991;50(4-6):731-41. Biomed Biochim Acta. 1991. PMID: 1801751

3

Human tumor cell urokinase-type plasminogen activator (uPA): degradation of the proenzyme form (pro-uPA) by granulocyte elastase prevents subsequent activation by plasmin.

Schmitt M, Kanayama N, Jänicke F, Hafter R, Graeff H. Schmitt M, et al. Among authors: graeff h. Adv Exp Med Biol. 1991;297:111-28. doi: 10.1007/978-1-4899-3629-5_10. Adv Exp Med Biol. 1991. PMID: 1837419

4

Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer.

Schmitt M, Jänicke F, Graeff H. Schmitt M, et al. Among authors: graeff h. Blood Coagul Fibrinolysis. 1990 Dec;1(6):695-702. Blood Coagul Fibrinolysis. 1990. PMID: 2133250

5

Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2.

Schmalfeldt B, Kuhn W, Reuning U, Pache L, Dettmar P, Schmitt M, Jänicke F, Höfler H, Graeff H. Schmalfeldt B, et al. Among authors: graeff h. Cancer Res. 1995 Sep 15;55(18):3958-63. Cancer Res. 1995. PMID: 7664262

6

Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy.

Kuhn W, Pache L, Schmalfeldt B, Dettmar P, Schmitt M, Jänicke F, Graeff H. Kuhn W, et al. Among authors: graeff h. Gynecol Oncol. 1994 Dec;55(3 Pt 1):401-9. doi: 10.1006/gyno.1994.1313. Gynecol Oncol. 1994. PMID: 7835780

7

Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.

Jänicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A, Graeff H. Jänicke F, et al. Among authors: graeff h. Cancer Res. 1994 May 15;54(10):2527-30. Cancer Res. 1994. PMID: 8168072

8

[Adjuvant therapy of breast cancer: present status and the significance of new prognostic factors].

Jänicke F, Graeff H. Jänicke F, et al. Among authors: graeff h. Rontgenpraxis. 1993 Dec;46(12):371-7. Rontgenpraxis. 1993. PMID: 8303469 Review. German. No abstract available.

9

Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer.

Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H, Graeff H. Jänicke F, et al. Among authors: graeff h. Breast Cancer Res Treat. 1993;24(3):195-208. doi: 10.1007/BF01833260. Breast Cancer Res Treat. 1993. PMID: 8435475

10

Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis.

Schmitt M, Wilhelm O, Jänicke F, Magdolen V, Reuning U, Ohi H, Moniwa N, Kobayashi H, Weidle U, Graeff H. Schmitt M, et al. Among authors: graeff h. J Obstet Gynaecol (Tokyo 1995). 1995 Apr;21(2):151-65. doi: 10.1111/j.1447-0756.1995.tb01089.x. J Obstet Gynaecol (Tokyo 1995). 1995. PMID: 8556577 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

219 results

Search Page

Filters